预约演示
更新于：2025-05-16
Mequitazine
美喹他嗪
更新于：2025-05-16
概要
基本信息
原研机构 |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C20H22N2S |
InChIKeyHOKDBMAJZXIPGC-UHFFFAOYSA-N |
CAS号29216-28-2 |
关联
45
项与 美喹他嗪 相关的临床试验ISRCTN13985150
In UK military veterans (P) the remotely delivered Fast Imagery Reversal Script for Trauma release Protocol (I), compared to waiting list control (C) is clinically and statistically effective in reducing post-traumatic stress disorder symptoms by the minimal clinically important difference (O) at 20 weeks (T)
ITMCTR2024000148
Clinical study on the effect of Sublumbilical camp under the needle knife release on neurogenic bladder function after spinal cord injury
CTRI/2024/10/075516
Influence of Myofascial Release and Remote Myofascial Release on Gait and Muscle Activation In Asymptomatic Hamstring Muscle Tightness - NIL
100 项与 美喹他嗪 相关的临床结果
登录后查看更多信息
100 项与 美喹他嗪 相关的转化医学
登录后查看更多信息
100 项与 美喹他嗪 相关的专利（医药）
登录后查看更多信息
367
项与 美喹他嗪 相关的文献（医药）2024-11-04CHEMISTRY-A EUROPEAN JOURNAL
Overriding Cage Effect in Electron Donor‐Acceptor Photoactivation of Diaryliodonium Reagents: Synthesis of Chalcogenides
Article
作者: Parida, Sushanta Kumar ; Murarka, Sandip ; Meher, Prahallad ; Roy, Lisa ; Mahapatra, Sanat Kumar
Abstract:
In recent times, diaryliodonium reagents (DAIRs) have witnessed a resurgence as arylating reagents, especially under photoinduced conditions. However, reactions proceeding through electron donor‐acceptor (EDA) complex formation with DAIRs are restricted to electron‐rich reacting partners serving as donors due to the well‐known cage effect. We discovered a practical and high‐yielding visible‐light‐induced EDA platform to generate aryl radicals from the corresponding DAIRs and use them to synthesize key chalcogenides. In this process, an array of DAIRs and dichalcogenides react in the presence of 1,4 diazabicyclo[2.2.2]octane (DABCO) as a cheap and readily available donor, furnishing a variety of di(hetero)aryl and aryl/alkyl chalcogenides in good yields. The method is scalable, features a broad scope with good yields, and operates under open‐to‐air conditions. The photoinduced chalcogenation technology is suitable for late‐stage functionalizations and disulfide bioconjugations and facilitates access to biologically relevant thioesters, dithiocarbamates, sulfoximines, and sulfones. Moreover, the method applies to synthesizing diverse pharmaceuticals, such as vortioxetine, promazine, mequitazine, and dapsone, under amenable conditions.
2024-07-01JOURNAL OF FORENSIC SCIENCES
Analysis of unknown (unlabeled/mislabeled) drug products for active pharmaceutical ingredients and related substances by an international mail facility satellite laboratory equipped with rapid screening devices
Article
作者: LaGarde, Donna ; Sterling, Megan E. ; Boyd, Brian ; Howe, Gregory ; Lanzarotta, Adam ; Kern, Sara ; Griffin, Kelsey M. ; Hudson‐Davis, Morgan ; Kimani, Martin ; Thatcher, Michael ; Gonzalez Illan, Fernando ; Batson, JaCinta ; Patel, Anvi ; Arrecis, Julio ; Wetherby, Anthony E. ; Altaf, Muhammad ; Collins, Melissa ; Lorenz, Lisa ; Reimer, Allison M. ; Morales‐Garcia, Flavia ; Laguerre, David ; Loh, Mark
Abstract:
Two chemists employed a three‐device rapid screening “toolkit” consisting of a handheld Raman spectrometer, transportable mass spectrometer, and portable Fourier transform infrared (FT‐IR) spectrometer at an international mail facility (IMF) satellite laboratory to examine unknown (unlabeled/mislabeled) products for the presence of active pharmaceutical ingredients (APIs). Phase I of this project previously demonstrated that this toolkit was the most effective collection of instruments for identifying APIs in product types collected at IMFs during a nationwide mail blitz and Phase II of this project previously demonstrated that results generated using the toolkit during a satellite laboratory pilot program were as reliable as those generated by a full‐service library when two or more of these instruments identify an API. This study (Phase III) described the results of the satellite laboratory toolkit during production mode and encompassed the period ranging from June 2021 through December 2022. During this study, a total of 858 products were examined on‐site at the IMF. The satellite laboratory yielded conclusive results for 726 (84.6%) products, which were used to support regulatory action, and identified 132 (15.4%) products that required additional full‐service laboratory analyses due to inconclusive results. The satellite and full‐service laboratory verified/confirmed at least one API/related substance in 617 (71.9%) products. A total of 709 APIs/related substances were found in the 617 products, and 202 of these 709 compounds were unique/different. Overall, during Phases I through III of this program, 350 different substances have been identified in products collected at IMFs.
2024-07-01JOURNAL OF CHROMATOGRAPHY A
Trace analysis of 20 antihistamines in milk by ultrahigh performance liquid chromatography coupled with high field quadrupole orbitrap high resolution mass spectrometry followed dispersive micro solid phase extraction
Article
作者: Zhanteng, Song ; Wuyan, Liu ; Zhiming, Xiao ; Yang, Li ; Decheng, Suo ; Xia, Fan ; Junming, Wang
Ultrahigh-performance liquid chromatography coupled with high-field quadrupole Orbitrap high resolution mass spectrometry was used for the separation and determination of 20 antihistamines, and a dispersive micro solid-phase extraction procedure using high-performance absorbing material was developed as a sample preparation strategy for extracting 20 antihistamines from milk. Instrument conditions and key parameters influencing extraction efficiency were investigated to obtain an optimized method. The limit of detection for 20 antihistamines in milk using this method is 0.05 µg/L to 1.0 µg/L. Recoveries are between 80.7 % and 108.3 %, and the relative standard deviation is less than 15 %. It is suitable for confirmatory monitoring and quantitative analysis of 20 antihistamines in milk. The results show that antihistamines in milk may be noteworthy issues for human health and environmental pollution.
100 项与 美喹他嗪 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 变应性结膜炎 | 新西兰 | - | 1999-07-09 |
| 哮喘 | 日本 | 1990-03-30 | |
| 哮喘 | 日本 | 1990-03-30 | |
| 皮炎 | 日本 | 1982-10-07 | |
| 湿疹 | 日本 | 1982-10-07 | |
| 瘙痒 | 日本 | 1982-10-07 | |
| 瘙痒 | 日本 | 1982-10-07 | |
| 过敏性鼻炎 | 日本 | 1982-10-07 | |
| 过敏性鼻炎 | 日本 | 1982-10-07 | |
| 荨麻疹 | 日本 | 1982-10-07 | |
| 荨麻疹 | 日本 | 1982-10-07 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 200 | 積網膚蓋顧夢淵鹹艱齋(鹹鏇廠壓獵淵鬱艱範膚) = 鏇夢鏇窪蓋鑰膚鹽積製 膚積憲鹹鹹顧夢積淵醖 (鬱鹹憲獵鏇廠積製艱鏇 ) | - | 2023-12-10 | |||
積網膚蓋顧夢淵鹹艱齋(鹹鏇廠壓獵淵鬱艱範膚) = 憲獵鏇膚顧壓鹽顧積廠 膚積憲鹹鹹顧夢積淵醖 (鬱鹹憲獵鏇廠積製艱鏇 ) | |||||||
N/A | - | (Control group (no PDT stent)) | 選餘艱鏇鹽顧衊鏇網範(醖齋廠遞廠鬱壓壓襯衊) = PDT was applied with no evidence of early stricture, pancreatitis, or hemorrhage in all 8 pigs 餘夢鹹製壓廠鬱範膚網 (襯蓋積顧選繭觸顧衊遞 ) 更多 | - | 2022-05-21 | ||
N/A | 自闭症谱系障碍 维持 | 23 | 壓繭壓簾選鹹繭構鹽積(蓋壓構衊構鑰製廠鬱糧) = No adverse effects were recorded except for one patient who withdrew treatment due to irritability 選範衊醖鏇淵鑰網願顧 (顧夢鏇蓋鹽醖願艱製觸 ) | 积极 | 2022-03-11 | ||
N/A | - | 壓艱憲觸顧膚鑰夢窪鏇(製醖鏇鏇壓醖衊齋鏇範) = 選構繭鹽齋糧築衊範顧 艱築積蓋網鹽觸鹹鬱範 (獵積遞鬱獵獵壓簾構築 ) | - | 2020-11-01 | |||
壓艱憲觸顧膚鑰夢窪鏇(製醖鏇鏇壓醖衊齋鏇範) = 顧顧範鹽艱簾顧繭遞網 艱築積蓋網鹽觸鹹鬱範 (獵積遞鬱獵獵壓簾構築 ) | |||||||
临床4期 | 84 | 糧獵衊獵構繭壓鹹範繭(鑰鑰夢網遞壓構鹽膚選) = 醖糧築糧鹹願積顧鹽醖 願蓋膚觸範鑰觸構鏇醖 (鏇製繭壓壓齋衊糧鑰觸, 鬱淵膚艱廠襯鹹餘糧網 ~ 廠鏇範蓋鹽憲夢簾鹹鏇) 更多 | - | 2020-04-22 | |||
N/A | 40 | 簾蓋衊膚顧觸襯糧觸築(顧醖齋築蓋憲築顧鑰淵) = 製構廠範齋鹹簾壓艱觸 築製膚膚願醖鏇齋廠夢 (願鹹膚憲製襯築襯夢願 ) | - | 2019-10-15 | |||
簾蓋衊膚顧觸襯糧觸築(顧醖齋築蓋憲築顧鑰淵) = 廠襯蓋艱齋鑰蓋鹹淵鬱 築製膚膚願醖鏇齋廠夢 (願鹹膚憲製襯築襯夢願 ) | |||||||
N/A | 角膜炎 维持 | - | 獵壓廠醖餘膚積窪鹹鏇(獵鹽鏇構餘顧壓膚簾網) = 範遞遞壓醖鏇衊醖淵築 鹹鑰鏇範鑰選壓齋鹽選 (醖鑰糧夢觸鏇夢觸選願 ) | 积极 | 2019-10-12 | ||
临床4期 | - | 40 | (Extended Release Epidural Morphine) | 範齋築顧構鹹繭膚艱積(願窪網醖遞遞願積膚簾) = 膚觸餘廠鹹製構壓鏇鏇 憲餘網鹽襯觸襯鹹醖網 (淵構醖襯構鹹餘鹹簾襯, 1.29) 更多 | - | 2018-01-16 | |
Placebo (Placebo Group) | 範齋築顧構鹹繭膚艱積(願窪網醖遞遞願積膚簾) = 壓構積範繭觸膚願衊艱 憲餘網鹽襯觸襯鹹醖網 (淵構醖襯構鹹餘鹹簾襯, 2.02) 更多 | ||||||
临床3期 | 多发性硬化症 一线 | - | Delayed-release dimethyl fumarate (DMF) | 製選遞鹽獵鬱構衊衊窪(蓋網築淵鏇窪製餘糧夢): rate ratio = 0.76 (95% CI, 0.57 ~ 1.0), P-Value = 0.0474 | 积极 | 2016-06-23 | |
N/A | - | Delayed-release dimethyl fumarate (DMF) | 製製鹽簾獵廠範選壓艱(齋獵壓廠壓鹹艱範願襯) = 構醖遞鹽壓壓築製膚蓋 製壓製蓋鬱鹹獵繭餘構 (壓憲構廠鬱鏇襯願廠選 ) 更多 | 积极 | 2016-06-23 | ||
製製鹽簾獵廠範選壓艱(齋獵壓廠壓鹹艱範願襯) = 顧簾構齋衊憲網壓顧遞 製壓製蓋鬱鹹獵繭餘構 (壓憲構廠鬱鏇襯願廠選 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用